EMA gives positive opinion on twelve new medicines

The European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion on twelve new medicines, a step that precedes final authorisation for marketing by the European Commission. The information available comes from a single statement reported by a specialised source; no further independent confirmation of the details of the individual recommendations is currently available.

The twelve recommendations cover a wide range of clinical areas. These include treatments for hypercholesterolaemia, a condition characterised by high levels of cholesterol in the blood, and for psoriasis, a chronic inflammatory skin disease. The committee also gave a favourable opinion on a medicine for age-related macular degeneration, an eye condition linked to ageing, and on a treatment for cholestatic pruritus, a symptom associated with liver and biliary tract dysfunction.

The recommendations also include a medicine for cerebral adrenoleukodystrophy, a rare genetic disease affecting the nervous system, as well as a product intended for post-exposure prophylaxis against Covid-19 and a treatment for neutropenia, a condition characterised by a reduction in white blood cells that increases the risk of infection. The package of opinions finally includes generic therapies in the cardiovascular and haematological fields, categories concerning respectively the circulatory system and blood disorders.

The committee’s positive opinion does not in itself mean the immediate availability of the medicines to patients: it is a recommendation that the Agency forwards to the European Commission, which then proceeds to the formal authorisation decision valid in all Member States of the Union. The available dossier does not specify the expected timeframe for this subsequent step, nor does it provide details on the clinical trials underlying the individual recommendations, on the number of patients involved in the trials, or on any conflicts of interest declared by the manufacturers.

The breadth of the therapeutic areas involved — from a rare disease of the nervous system to a widespread condition such as hypercholesterolaemia — reflects the ordinary functioning of the committee, which periodically examines dossiers from different pharmaceutical companies and evaluates them according to scientific and regulatory criteria. The next step, the European Commission’s decision, will determine the actual timeframe within which these treatments will become available in the Member States.